Who Suffers From Lilly's Evacetrapib Failure?

The latest failure of a cholesteryl ester transfer protein (CETP) inhibitor, this time Eli Lilly & Co.'s evacetrapib, likely marks the demise of the once-promising drug class. But while Lilly and fellow CETP sponsors Merck & Co. and Amgen Inc. are hurting, there’s a silver lining for others.

The failure of Lilly's highly anticipated cholesterol drug evacetrapib is unlikely to have a major impact on the big pharma's...